Vermillion Delisted from Nasdaq; Will Trade on Pink Sheets | GenomeWeb
Home » Vermillion Delisted from Nasdaq; Will Trade on Pink Sheets

Vermillion Delisted from Nasdaq; Will Trade on Pink Sheets

Sep 25, 2008
NEW YORK (GenomeWeb News) – Vermillion said today that it has been delisted from the Nasdaq Capital Market as of this morning due to noncompliance with Nasdaq’s minimum requirements.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Apr 26, 2016

Nasdaq Warns Transgenomic of Failure to Comply With Listing Requirements

Jan 29, 2016

Nanosphere Receives Deficiency Letter From Nasdaq

Dec 28, 2015

CombiMatrix Shares Face Potential Nasdaq Delisting

Dec 29, 2015

WaferGen Receives Notification of Potential Nasdaq Delisting

Feb 17, 2016

CombiMatrix Regains Compliance With Nasdaq Listing Requirement

Nov 24, 2015

Nasdaq to Delist BG Medicine’s Stock

The Scan

This Week in Nature

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Some Cold Water

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA-Based Wanted Sketch

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

So, What's This Exactly?

Researchers discuss the need for antibody standards at a meeting, NPR reports.

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.